FDA and Rare Disease Drug Development, from FDA Week
June 29, 2010 // [FDA Week, http://insidehealthpolicy.com/] FDA is currently in the middle of a flurry of activity aimed at better focusing its regulation of rare disease treatments, but the agency disappointed some outside advocates by delaying the possibility of creating a special rare disease review division within FDA for at least a year. That [...]